Navigation Links
AML Therapeutics Market in the 6MM Worth $430.7m in 2017 Says a New Research Report Available at ReportsnReports.com
Date:8/15/2013

Dallas, TX (PRWEB) August 15, 2013

Key R&D trends in the Acute Myeloid Leukemia market include developing therapies for the patients with greatest unmet need, particularly the elderly, developing combination therapies, and investigating new targets (i.e. FLT3) involved in the pathogenesis of AML. Despite high levels of unmet need, uptake of new drugs will be limited, as KOLs are relatively unimpressed by these agents. Therefore, ample market opportunity will remain at the end of the forecast period. To circumvent historical difficulties with regulatory approval, companies are designing early- and late-stage clinical trials more rigorously. Randomization of early-stage trials is critical, and the designation of overall survival (OS) as the primary endpoint of pivotal studies is mandatory. Despite the hype around FLT3 inhibitors, KOLs are unconvinced that these drugs will be successful as monotherapies in AML.

This new research report published in Aug 2013, “OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017” ( http://www.reportsnreports.com/reports/267301-opportunityanalyzer-acute-myeloid-leukemia-aml-opportunity-analysis-and-forecasts-to-2017.html ), focuses on the remaining opportunity in AML exclusive of the acute promyleocytic leukemia (APL) subtype. The scope of this research includes: Overview of AML, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management; Topline AML therapeutics market revenue from 2012–2017. Annual cost of therapy, and peak pipeline drug sales of drugs launching during this forecast period are included; Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strate
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... BOTHELL, Wash. , March 6, 2015   ... a leading developer, manufacturer and marketer of proprietary clinical ... media and precision thermal shipping products ... announced that the Company,s fourth quarter and full year 2014 financial ... and that the Company will host a conference call ...
(Date:3/5/2015)... LifeCell Dx and its founder, Dr. ... an Advanced Semen Analysis before they do anything else ... all risk factors for struggling couples.Too often, the traditional ... of the infertility. Infertility is fairly equally divided between ... simplest, least complicated and inexpensive analysis that provides far ...
(Date:3/5/2015)... and TORONTO , March 5, ... a clinical-stage company developing new therapeutics and molecular diagnostics ... that William G. Rice , Ph.D., Chairman, President ... 27th Annual ROTH Conference on Tuesday, March 10 th ... Carlton, Laguna Niguel, CA. Dr. ...
(Date:3/5/2015)... The next implants made from the ... mark (European) approval. The CE mark is necessary for ... and the European Union. Following the Class IIb approval ... implants supplied by the Turkey-based company Osimplant for the ... Cervical Expandable Bladed HA PEEK Cage line of spinal ...
Breaking Biology Technology:BioLife Solutions to Report Fourth Quarter and Full Year 2014 Financial Results and Provide Business Update on March 12, 2015 2LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3
... 26 Bionovo, Inc.,(Nasdaq: BNVI ) (the "Company") today ... of common stock at a price to the public of,$2.50 ... stock,at $3.50 per share at a price of $0.10 per ... to purchase up to an additional 15% of,the offering to ...
... Convention Center during the ... Sunday, October 28, LOS ANGELES, Oct. 26 ASTRO Booth #2303 ... of The,Group Room, a live radio talkshow about cancer that will air ... Los Angeles Convention Center on Sunday, Oct. 28. The Group Room ...
... Commence Phase 2 Clinical Program for KOS-1584, ... Biosciences,Incorporated (Nasdaq: KOSN ) today announced ... development and commercialization,collaboration. The collaborative research, development ... will terminate,after a transition period, following which ...
Cached Biology Technology:Bionovo Announces the Pricing of Public Offering of Shares of Common Stock 2Bionovo Announces the Pricing of Public Offering of Shares of Common Stock 3Varian Medical Systems Sponsors Special Broadcast of The Group Room(R), a Live Radio Talkshow About Cancer 2Varian Medical Systems Sponsors Special Broadcast of The Group Room(R), a Live Radio Talkshow About Cancer 3Kosan to Reacquire Epothilone Program From Roche 2Kosan to Reacquire Epothilone Program From Roche 3Kosan to Reacquire Epothilone Program From Roche 4
(Date:2/25/2015)... LITTLE ROCK, Ark. , Feb. 25, 2015 ... of software and billing in the Health and ... software as well as to MYiCLUBonline.  The latest ... MYiCLUBonline and the inclusion of cardless check-in via ... demonstrated for the first time through interactive displays ...
(Date:2/19/2015)... , Feb .19, 2015 Research and ... the addition of the "Military Electro-Optical / ... Sensor Technology, by Platform - Forecast to 2020" ... The military electro-optical/infrared systems market is expected to ... CAGR of 7.71%. This report segments ...
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... Cincinnati Children,s Hospital Medical Center has developed an antibody ... afflict hospitalized patients who receive central lines. Margaret ... and her team developed the antibody, which prevents ... the formation of biofilm in a rat model of ...
... The Entomological Society of America is pleased to announce ... be presented at Entomology 2013, ESA,s 61st Annual Meeting ... PROFESSIONAL AWARDS RECOGNITION AWARD IN ENTOMOLOGY ... recognizes entomologists who are making significant contributions to agriculture. ...
... The search for the cause of multiple sclerosis, a debilitating ... the United States, has confounded researchers and medical professionals for ... New Jersey Medical School, has now found an important clue ... research on the origins of MS has focused on the ...
Cached Biology News:Entomological Society of America announces 2013 awardees 2Entomological Society of America announces 2013 awardees 3Entomological Society of America announces 2013 awardees 4Entomological Society of America announces 2013 awardees 5Entomological Society of America announces 2013 awardees 6Entomological Society of America announces 2013 awardees 7Entomological Society of America announces 2013 awardees 8Entomological Society of America announces 2013 awardees 9Entomological Society of America announces 2013 awardees 10Entomological Society of America announces 2013 awardees 11Entomological Society of America announces 2013 awardees 12Entomological Society of America announces 2013 awardees 13Entomological Society of America announces 2013 awardees 14Entomological Society of America announces 2013 awardees 15Multiple sclerosis appears to originate in different part of brain than long believed 2Multiple sclerosis appears to originate in different part of brain than long believed 3
...
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Complete kit for all types of yeast two-hybrid ... Choice of two bait ... baits , Triple ... Complete set of ...
Biology Products: